EFTA01108234.pdf

LabCoro Raritan LaDUOrP 69 First Avenue Raritan, NJ 08869-1800 Phone: 877-547-6837 ‘,..-...t.a ',anon., Pat ID t narrnl Numb... Acctann Nunthei Act aunt Ma. NIIIIIiICI Rini'', 2 6 3-48 0-2797 -0 CNT31143092 31143092 212-535-1012 70 'awn I an NaltDC Account We, EPSTEIN Woodson Merrell raftnehtitUkNanw JEFFREY I.,,,,ifly. PanmPhow Inafl'oltiat: 44 E 67th St ***-**-3348 212-772-9416 New York NY 10065 Arc ilAtIDI >atc of limb \., lawny 60/08/00 01/20/53 M RetneAtMle, AddamtnlInhantanim 9 E 71ST ST NEW YORK NY 10065 UPIN: A62553 Dale and lanes Collin:led Date I iteicd Date and law Reptn.:41 Inn .ntaa Nam.: Nil 11k) m, tan Ill 09/20/13 14:00 09/21/13 09/25/13 15:06ET MERRELL , W 1023153509 MERRELL let( ,lend MIR tipoProfile( CBC With Differential/Platelet: Comp. Metabol'c Panel (14); PE+InterplEfx IFE).S; Lyme Ab/Western Blot Reflex Iron and TIBC: Testosterone,Free+Weakly Bound; Prolactin; DHEA-Sulfate: Homocyst(e)ine, Plasma; C-Reactive Protein. Card'ac: Hemoglobin Ale; Prostate-Specific Ag, Serum TSH: Vitamin D, 25-Hydroxy: Uric Acid, Serum; GOT; Insulin; Ambiguous Test Order; Ferritin, Serum; Request Problem TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB N1414 LipoProfile LDL Particle Number 01 LDL-P 2111 High nmol/L <1000 01 Low < 1000 Moderate 1000 - 1299 Borderline-High 1300 - 1599 High 1600 - 2000 Very High > 2000 Lipids 01 LDL-C NOTES: mg/dL <100 01 LDL-C cannot be calculated because triglycerides are > 400 mg/dL. Optimal • 100 Above optimal 100 - 129 Borderline 130 - 159 High 160 - 189 Very high • 189 HDL-C Low mg/dL >=40 01 Triglycerides High mg/dL <150 01 Cholesterol, Total High mg/dL <200 01 LDL and HDL Particles 01 HDL-P (Total) 28.7 Low umol/L >= 30.5 01 Small LDL-P 1548 High nmol/L <= 527 01 LDL Size 19.8 Low nm > 20.5 01 *** INTERPRETATIVE INFORMATION*** PARTICLE CONCENTRATION AND SIZE <--Lower CVD Risk Higher CVD Risk--> LDL AND HDL PARTICLES Percentile in Reference Population HDL-P (total) High 75th 50th 25th Low >34.9 34.9 30.5 26.7 <26.7 EPSTEIN, JEFFREY I 263-480-2797-0 SeqS5515 09/25/13 15:06 ET FINAL REPORT Page 1 of 6 This document contains private and confidential health information protected by state and federal law 02004-13 Laboratory Corporation of America O Holdings If you have received this document in tam, please call 800-631-5250 All Rights Reserved DOC I Ver. 1.49 EFTA01108234  LabCorp Raritan LabCorp 69 First Avenue Raritan, NJ 08869-1800 Phone: 877-547-6837 NIICIII Name %man r.4 mho EPSTEIN, JEFFREY 263-480-2797-0 Ac“Ainl NtonIrr Patient II) Control NumIxt 1)44r and lath Colleck14/4 Dare Repork4 %c, Agt(Y/114/1)1 I ki,.. .• . 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Small LDL-P Low 25th 50th 75th High <117 117 527 839 >839 LDL Size <-Large (Pattern A)-> <-Small (Pattern B)-> 23.0 20.6 20.5 19.0 Insulin Resistance Score 01 LP-IR Score 100 High <= 45 01 LP-IR Score is inaccurate if patient is non-fasting. The LP-IR Score combines information from lipoprotein particle concentration and size to give improved assessment of insulin resistance and diabetes risk. Small LDL-P, LDL Particle Size, HDL-Particle, and LP-IR Score have been validated by LipoScience but not cleared by US FDA; the clinical utility of these test results has not been fully established. INSULIN RESISTANCE MARKER <--Insulin Sensitive Insulin Resistant--> Percentile in Reference Population Insulin Resistance Score LP-IR Score Low 25th 50th 75th High <27 27 45 63 >63 CBC With Differential/Platelet WBC 6.4 xl0E3/uL 3.4 10.8 02 RBC 5.24 x10E6/uL 4.14 5.80 02 Hemoglobin 15.3 g/dL 12.6 17.7 02 Hematocrit 43.9 37.5 51.0 02 MCV 84 fL 79 97 02 MCH 29.2 P9 26.6 33.0 02 MCHC 34.9 g/dL 31.5 35.7 02 RDW 14.3 12.3 15.4 02 Platelets 269 x10E3/uL 155 379 02 Neutrophils 56 40 74 02 Lymphs 31 14 46 02 Monocytes 8 4 12 02 Eos 4 0 5 02 Basos 1 0 3 02 Neutrophils (Absolute) 3.6 x10E3/uL 1.4 7.0 02 Lymphs (Absolute) 2.0 xl0E3/uL 0.7 3.1 02 Monocytes(Absolute) 0.5 x10E3/uL 0.1 0.9 02 Eos (Absolute) 0.3 x10E3/uL 0.0 0.4 02 Baso (Absolute) 0.1 x10E3/uL 0.0 0.2 02 Immature Granulocytes 0 0 2 02 Immature Grans (Abs) 0.0 x10E3/uL 0.0 0.1 02 EPSTEIN, JEFFREY 263-480-2797-0 Seq/5515 09/25/13 15:06 ET FINAL REPORT Page 2 of 6 This document contains private and confidential health infamation protected by slate and federal law. O200S-13 Laboratory Corporation of America Holdings If you have received this document in amt, please tall 800-631-5250 All Rights Reserved DOC I Ver. 1.49 EFTA01108235  LabCorp Raritan LabCorp labadbaryOanaotalsolDnifx 69 First Avenue Raritan, NJ 0RR69- R00 Phone: 877-547-6837 Piww%amm- si., on. n N., a I‘. , EPSTEIN, JEFFREY 263-480-2797-0 movie Ntradwi ration In Control Month:, Dam and I my CoII4% led Dale Iterotkat S. l\el \ %I 0 I ltt, .4 Bulb 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAB Comp. Metabolic Panel (14) Glucose, Serum (1103 High) mg/dL 65 - 99 02 BUN 19 mg/dL 8 - 27 02 Creatinine, Serum 0.94 mg/dL 0.76 - 1.27 02 eGFR If NonAfricn Am 88 mL/min/1.73 >59 eGFR If Africn Am 101 mL/min/1.73 >59 BUN/Creatinine Ratio 20 10 - 22 Sodium, Serum 139 mmol/L 134 - 144 02 Potassium, Serum 4.1 mmol/L 3.5 - 5.2 02 Chloride, Serum 98 mmol/L 97 - 108 02 Carbon Dioxide, Total 19 mmol/L 19 - 28 02 Calcium, Serum 10.1 mg/dL 8.6 - 10.2 02 Protein, Total, Serum 7.3 g/dL 6.0 - 8.5 02 Albumin, Serum 4.5 g/dL 3.6 - 4.8 02 Globulin, Total 2.8 g/dL 1.5 - 4.5 A/G Ratio 1.6 1.1 - 2.5 Bilirubin, Total 0.6 mg/dL 0.0 - 1.2 02 Alkaline Phosphatase, S 58 IU/L 44 - 102 02 AST (SCOT) IU/L 0 - 40 02 ALT (SGPT) High Iva 0 - 44 02 PE+Interp(Rfx IFE),S Albumin 4.2 g/dL 3.2 - 5.6 02 Alpha-J -Globulin 0.2 g/dL 0.1 - 0.4 02 Alpha-2-Globulin 0.8 g/dL 0.4 - 1.2 02 Beta Globulin 1.0 g/dL 0.6 - 1.3 02 Gamma Globulin 1.0 g/dL 0.5 - 1.6 02 M-Spike Not Observed g/dL Not Observed 02 Globulin, Total 3.1 g/dL 2.0 - 4.5 A/G Ratio 1.4 0.7 - 2.0 Please note: 02 Protein electrophoresis scan will follow via computer, mail, or courier delivery. Interpretation(See Below) 02 The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. Lyme P.b/Western Blot Reflex Lyme IgG/IgM Ab 0.92 index High 0.00 - 0.90 02 Negative <0.91 Equivocal 0.91 - 1.09 Positive >1.09 Note: The CDC currently advises that Western blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western blot. EPSTEIN, JEFFREY 263-480-2797-0 Seq a 5515 09/25/13 15:06 ET FINAL REPORT Page 3 of 6 This document contains private and confidential health information protected by state and federal law O2004-13 Lehman:ay Corporation of America 0 Holdings If you have received this document in enor, please call 800-631-5250 All Rights Reserved DOCI Ver. 1.49 EFTA01108236  LabCorp Raritan LabQorp 69 First Avenue Raritan, NJ 08869-1800 I'Insne: 877-547-6837 PateentNarne EPSTEIN, JEFFREY 263-480-2797-0 A..ouni NIMLIVt l'anent ID Control Number laic midTune Collected Dale Reported fin April rat I 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESIJIff FLAG UNITS RE773tENCE IWPERVAL LAB Lyme Ab Interp.,EIA Equivocal 02 Lyme Ab IgG by WB: 02 IgG P93 Ab. Absent 02 IgG P66 Ab. Absent 02 IgG P58 Ab. Present Abnormal 02 IgG P45 Ab. IgG P41 Ab. IgG P39 Ab. Absent Present Abnormal Absent 0 02 02 02 IgG P30 Ab. Absent 02 IgG P28 Ab. Absent 02 IgG P23 Ab. Absent 02 IgG P18 Ab. Absent 02 Lyme IgG WB Interp. Negative 02 Positive: 5 of the following Borrelia-specific bands: 18,23,28,30,39,41,45,58, 66, and 93. Negative: No bands or banding patterns which do not meet positive criteria. Lyme Ab IgM by WB: 02 IgM P41 Ab. Absent 02 IgM P39 Ab. Absent 02 IgM P23 Ab. Absent 02 Lyme IgM WB Interp. Negative 02 Note: An equivocal or positive EIA result followed by a negative Western Blot result is considered NEGATIVE. An equivocal or positive EIA result followed by a positive Western Blot is considered POSITIVE by the CIDC. Positive: 2 of the following bands: 23,39 or 41 Negative: No bands or banding patterns which do not meet positive criteria. Criteria for positivity are those recommended by CDC/ASTPHLD. p23=0sp C, p41=flagellin Note: Sera from individuals with the following may cross react in the Lyme Western Blot assays: other spirochetal diseases (periodontal disease, leptospirosis, relapsing fever, yaws, and pinta); connective autoimmune (Rheumatoid Arthritis and Systemic Lupus Erythematosus and also individuals with Antinuclear Antibody); other infections (Rocky Mountain Spotted Fever; Epstein-Barr Virus, and Cytomegalovirus). Lyme Disease Ab, Quant, IgM <0.91 index 0.00 - 0.90 02 Negative <0.91 I EPSTEIN, JEFFREY I 263-480-2797-0 I Sai#55O 09/25/13 15:06 ET FINAL REPORT Page 4 of 6 This document contains private and confidential health information protected by state and federal law. O2001-13 Laboratory Corporation of America 0 Holdings If you have received this document in error. please call 800-631-5250 All Rights Reserved D0CI Ver: 1.49 EFTA01108237  LabCorp Raritan LabCorp labotOlOry COFFC4/“. al AniCet 69 First Avenue Raritan. NJ 08869-1800 PlumeArn-547-MO7 p.i.o.i.m... .F.....i."‘",,N. EPSTEIN, JEFFREY 263-480-2797-0 \..,..aNwrIvr NhouID CotwANutithct ou. ml tun; con,ord nu, toward Sc , %).,i ni .l ,, I )ilt 'il th rill 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTS RESULT FLAG UNITS REFERENCE INTERVAL LAS Equivocal 0.91 - 1.09 Positive >1.09 Note: IgM levels may peak at 3-6 weeks post infection, then gradually decline. FDA currently advises that Western Blot testing be performed following all equivocal or positive EIA results. Final diagnosis should include appropriate clinical findings and a positive EIA which is also positive by Western Blot. Iron and TIBC Iron Bind.Cap. ITIBC) 329 ug/dL 250 - 450 UIBC 244 ug/dL 150 - 375 02 Iron, Serum 85 ug/dL 40 - 155 02 Iron Saturation 26 % 15 - 55 Testosterone,Free+Weakly Bound Testosterone, Serum 178 Low ug/dL 348 - 1197 02 Prolactin 4.2 ng/mL 4.0 - 15.2 02 DHEA-Sulfate 207.7 ug/dL 51.7 - 295.0 02 **Please note reference interval change** Homocyst(e)ine, Plasma 12.8 umol/L 0.0 - 15.0 02 C-Reactive Protein, Cardiac 1.04 mg/L 0.00 - 3.00 02 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc ( .1 5 :, High % 4.8 - 5.6 02 Increased risk for diabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.8 ng/mL 0.0 - 4.0 02 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. EPSTEIN, JEFFREY 263-480-2797-0 Seq45515 09/25/13 15:06 ET FINAL REPORT Page 5 of 6 This document contains pnvate and confidential health information prowled by same and federal law. 02004-13 laboratory Corporation of America m Holdings If you have received this dccumcnt in error. please call S00-631-5250 All Rights Reserved DOCI Vec 1.49 EFTA01108238  LabCorp Raritan LabCorp 69 First Avenue Raritan. NJ 08869-1800 Phone: 877-547-6837 PammNow SpumenMMer EPSTEIN, JEFFREY 263-480-2797-0 A:ckvm Nombre Diked ID Coned Number Dune and him(( nand Dale NSW( Wki Se\ Apt YAM flak .4 KIM 31143092 CNT31143092 09/20/13 14:00 09/25/13 M 60/08/00 01/20/53 TESTR ItZSULT FLAG UNITS REFERENCE INTERVAL LAB Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSH 1.680 uIU/mL 0.450 4.500 02 Vitamin D, 25-Hydroxy 41.4 ng/mL 30.0 - 100.0 02 Vitamin D deficiency has been defined by the institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Hinkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. Uric Acid, Serum Uric Acid, Serum 7.1 mg/dL 3.7 - 8.6 02 Please Note: 02 Therapeutic target for gout patients: <6.0 GGT 18 IU/L 0 - 65 02 Insulin High uIU/mL 2.6 - 24.9 02 Ambiguous Test Order 02 Attempts to contact your facility to clarify an ambiguous test order were unsuccessful. Please contact the laboratory to verify the request. Specimens are outinely held for 7 days from date of receipt. Ambiguous test order: (1 A 028240 0/4. 49 AAP) Ferritin, Serum 121 ng/mL 30 - 400 02 Request Problem 03 Test Not Performed. Specimen is lipemic. TEST: 143257 Testost., % Free+Weakly Bound Panel: 143255 01 67LipoScience Inc Dir: Deanna Franke, PhD 2500 Sumner Blvd, Raleigh, NC 27616-3235 02 RN LabCorp Raritan Dir: Araceli B Reyes, MD 69 First Avenue, Raritan, NJ 08869-1800 03 BR LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington, NC 27215-3361 For inquiries, the physician may contact Branch: 800-631-5250 Labs 877-547-6837 EPSTEIN, JEFFREY 263-480-2797-0 Seg 5515 09/25/13 15:06 ET FINAL REPORT Page 6 of 6 This document contains private and confidential health inferential protected by state and federal law. 02004-13 Laboratory Corporation of America O Holdings If you have received this document in error. please call 800-631-5250 All Rights Reserved DOCI Ver: 1.49 EFTA01108239 Laboratory Corporation of America Special Chemistry Department Raritan, New Jersey Serum Protein Electrophoresis Specimen Number 263480279706 Account No./Name: 31143092-Woodson Sorrell Total Protein: 7.3 DID: Patient Name: EPSTEIN,JEFFREY Account Address 1: Patient Id: Account Address 2: 44 E 67th St Birthdate: 20-JAN-1953 Account Address 3: New York, NY 10065 ,t _ SP/FE SPE Split Beta Sample 9 09-23-2013 12:45:08:08 Statua.Ok Fraction ts g/dL Range Albumin 58.1 4.2 3.2 5.6 Alpha 1 2.7 0.2 0.1 0.4 Alpha 2 11.2 0.8 0.4 1.2 Beta 13.9 1.0 0.6 1.3 Gamma 14.1 1.0 0.5 1.6 Total 7.3 6.0 8.5 Comment The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. EFTA01108240  LabCorp Raritan LabCpip 69 First Avenue Raritan, NJ 08869-1800 Phone:800-631-5250 SmimenNwatta Pawn In CoMmINum4m AcemmiNmalla AccmmIllamwNumlw RoMe 263-480-2797-1 CNT31143092 31143092 212-535-1012 70 l'aMmIli4Nme AccamlAddlmA EPSTEIN Woodson Merrell Pamm him Name I Fmcm SNAIL< Nair JEFFREY Blum SSP Pa wag Illtom Fool VAtime 44 E 67th St ***-**-3348 212-772-9416 New York NY 10065 Ape I WMMI Usle 4 Rob Sex ',tom', 60/08/00 01/20/53 I M PaImm Aare. Atlamoft4 IMmilimam 9 E 71ST ST NEW YORK NY 10065 UPIN: A62553 Die aid 'rime Collectal IWelted Mole mai Imm Recamied PI9vam Name SPI l'It>.4,4o ID 09/20/13 14:00 09/25/13 09/26/13 09:0SET MERRELL , W 1023153509 MERRELL Icd lkactril ESN and LH; Written Authorization TEST/3 RESULT FLAG UNITS RRIT.RIniCIS INTERVAL LAB FSH and LH LH 5. 3 mIU/mL 1.7 - 8.6 01 FSH 4. 5 mIU/mL 1.5 - 12.4 01 Written Authorization Written Authorization Received. 01 Authorization received from SIGNATURE FILE 09-25-2013 Logged by Anca Orban 01 RNLabCorp Raritan Dir: Araceli B Reyes, MD 69 First Avenue, Raritan, NJ 08869-1800 For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-631-5250 EPSTEIN, JEFFREY 263-480-2797-1 Seq a 5522 09/26/13 09:06 ET FINAL REPORT Page 1 of 1 This document contains private and confidential health information protected by sum and federal law. O2004-I3 Laboratory Calash's:I of America Holdings If you have received this document in error, please call 800-631-5250 All Rights Reserved DOCI Ver 149 EFTA01108241  LabCorp Raritan 69 First Avenue =ere; Metro'n or....cr Raritan. NJ 08869-1800 Phone 800-762-4344 N... on,,, "...mix, l'aNcin II) C oimol Number Accous Number Mawr Phme Nmnivr Rome 263-480-3235-0 04K31143092 31143092 212-535-1012 70 i.awi,i I.nt Nom: A.,ouni Atkirr, EPSTEIN Woodson Merrell I . Ilk Of IRA NJITIC Tabun, Mold!. N.IIIIC JEFFREY rancid Vol IN ICIII II me Ltd ',Iwo,. 44 E 67th St ***_**_3348 212-772-9416 %de ol limit New York NY 10065 Ap: t‘Al/IN Sea I ...ialt: 60/08/00 01/20/53 M l'atient Atkin.. Addonmal !Moon-mon 9 EAST 71ST ST NEW YORK NY 10065 UPIN: A62553 iiai, ari t um Collected l/oc I meted flaw and I mte Kt-rimed llog..13II Name Nil Pity.Nsan ID 09/20/13 14:00 09/21/13 09/26/13 09:05ET MERRELL , W 1023153509 Lp-PLA2 TESTS RESULT FLAG UNITS REFERENCE INTERVALMAS LP-PLA2 137 ng/mL 131 - 199 01 Low Risk <200 Moderate Risk 200 - 235 High Risk >235 01 BN LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington. NC 27215-3361 For inquiries, the physician may contact Branch: 800-631-5250 Lab: 800-762-4344 EPSTEIN, JEFFREY 263-480-3235-0 SeqW5523 09/26/13 09:06 ET FINAL REPORT Page 1 of 1 This document contains private and confidemial health information married by slam and federal law.